FDA APPROVES RIABNI , A BIOSIMILAR TO RITUXAN® , FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS Market News
Final Data From Phase 3 ASCENT Study Demonstrates Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC Pharmaceutical Investing
Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo Plus Yervoy with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer Pharmaceutical Investing
Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo Plus Yervoy in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Pharmaceutical Investing
NEW HEAD-TO-HEAD DATA SHOW VECTIBIX® DEMONSTRATED SUPERIOR OVERALL SURVIVAL COMPARED TO BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN JAPANESE PATIENTS WITH WILD-TYPE RAS COLORECTAL CANCER Market News
Tecartus® Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-Up of Two Pivotal Studies Including Longest Ever Follow-Up of a CAR T-cell Therapy in Mantle Cell Lymphoma Pharmaceutical Investing
Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds AbbVie, Inc. Investors with Substantial Losses to Contact the Firm Pharmaceutical Investing
Sub-analyses of Landmark ZUMA-7 Trial Reinforce Yescarta® CAR T-cell Therapy Superiority Over Standard of Care as Initial Treatment for Patients With Relapsed or Refractory Large B-cell Lymphoma Pharmaceutical Investing
Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients Pharmaceutical Investing
Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients Pharmaceutical Investing
Bristol Myers Squibb Withdraws Supplemental Biologics License Application for Reblozyl® for Non-transfusion Dependent Beta Thalassemia Pharmaceutical Investing
